Professor Ernst Wolvetang

 - Chief Investigator

Professor Wolvetang is both one of the leading iPS cell researchers in Australia and one of the few stem cell biologists with the necessary cross-disciplinary expertise that is required for the development of the microfluidic platforms that will be used to generate and direct human iPSC, as proposed in this bid. His leadership in the ASCC funded “Reprogramming and induction of pluripotency” stream has made this stream one of the more successful programs in that endeavour and has, in a short time, given considerable impetus to iPSC research in Australia.

His laboratory is the first laboratory world-wide to generate a non-viral human iPSC-based disease model. He has further investigated the genetic and epigenetic stability of human ES cells cultured under various conditions, experience that will be invaluable when analysing the safety of human iPSC. In a short time, he has forged international collaborations with a number of researchers in the iPSC and epigenetic research fields.

His vision to enable iPSC research in Australia and bring together leading stem cell researchers around this theme has already lead to an extensive network of collaborations, including many of Stem Cells Australia’s CI. The Wolvetang group will bring the unique combination of iPS cell generation and analytic capability, screening platform development (in close collaboration with the Cooper-white group) and epigenetic and genetic stability expertise to the Stem Cells Australia initiative.